Introduction to Thalassaemia

Thalassaemia is a genetic blood disorder where the body makes an abnormal form of hemoglobin – the protein in red blood cells that carries oxygen throughout the body. 

Patients diagnosed with Thalassaemia may require regular blood transfusions to raise their hemoglobin blood levels. This can lead to iron build-up in the body’s tissue and organs – also referred to as iron overload. As iron can be toxic, too much of it can damage tissue. Excessive iron accumulates in the heart, liver, lungs, brain, and other organs, which highly increases the risk of other diseases and even life-threatening conditions.

If a patient with Thalassemia is experiencing iron overload from frequent blood transfusions, they may require an iron removal or chelation therapy. One medication approved for this is Desferal™, which is infused subcutaneously using an infusion pump and infusion set. Desferal™ is given over a 8-12 hour period, often overnight. The treatment can be performed daily, or 5-7 times a week.*

^{* According to Desferal™ Summary of Product Characteristics (SPC) by Novartis Pharmaceuticals UK Ltd.}

The neria™ product range

neria™ infusion sets are tested (in vitro) for use with Desferal™.¹

1. Product Specifications	neria™
   Cannula	Stainless Steel
   Insertion angle	90 degrees
   Disconnection feature	No
   Needle / Introducer needle guage	G27 or G29
   Needle lengths	6, 8, 10 or 12 mm
   Tubing lengths	60, 80, 110 cm
   Adhesive	Built-in
   Needle safety	No
   Priming volumes	60 cm @ 0.10 ml 80 cm @ 0.12 ml 110 cm @ 0.15 ml

    

   ^{1. Statement - Overview of Drug/Device Compatibility Test for the neria™ Range. 24. February 2020. AP-020446-MM. Data on file. Unomedical A/S.}